title: Costs and benefits of influenza vaccination: more evidence, same challenges.
abstract: Seasonal influenza vaccination coverage in most EU/EEA remains suboptimal. Providers' and users' confidence in influenza vaccines is undermined by reports of moderate to low vaccine effectiveness and by the lack of solid evidence on disease burden. A study from Preaud and co. indicates that even with current levels of vaccine effectiveness, increasing vaccination coverage would significantly reduce disease burden and health cost. The results of the study should be interpreted cautiously because some of the assumptions are not generalizable or are imprecise, especially those on vaccine coverage, disease burden and health cost. Increasing vaccination coverage in EU/EEA countries is very challenging. Multifaceted approaches and country specific strategies are needed to address vaccine hesitancy in health care workers and in the population, and to manage organisational and financial obstacles. One key element for increasing vaccination coverage is the development of better influenza vaccines, e.g. vaccines that are more effective, provide longer lasting immunity and do not require annual administration. Vaccine producers should consider this as the highest research priority in the field of influenza vaccine development.
authors.affiliation: European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden. Bruno.Ciancio@ecdc.europa.eu.
authors.forename: Bruno Christian
authors.initials: BC
authors.lastname: Ciancio
authors.forename: Giovanni
authors.initials: G
authors.lastname: Rezza
mesh_terms: D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D011247:Pregnancy; D014611:Vaccination
chemical_list: D007252:Influenza Vaccines
references.citation: Clin Infect Dis. 2012 Oct;55(7):951-9
references.pmid: 22843783
references.citation: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004876
references.pmid: 16856068
references.citation: Euro Surveill. 2013 Jan 31;18(5):
references.pmid: 23399425
references.citation: Euro Surveill. 2014 Apr 24;19(16):20780
references.pmid: 24786262
references.citation: Vaccine. 2010 Aug 23;28(37):5931-3
references.pmid: 20637760
references.citation: PLoS One. 2011;6(11):e27622
references.pmid: 22110695
references.citation: Infection. 2009 Jun;37(3):197-202
references.pmid: 19139807
references.citation: BMC Public Health. 2014 Aug 07;14:813
references.pmid: 25103091
references.citation: Vaccine. 2007 Feb 19;25(9):1669-75
references.pmid: 17129642
references.citation: Med Mal Infect. 2008 Nov;38(11):574-85
references.pmid: 18954950
references.citation: Lancet Infect Dis. 2013 Jan;13(1):7-9
references.pmid: 23257219
references.citation: Euro Surveill. 2009 Oct 01;14(39):
references.pmid: 19814961
references.citation: Euro Surveill. 2012 Sep 27;17(39):
references.pmid: 23041022
references.citation: Cochrane Database Syst Rev. 2010 Jul 07;(7):CD001269
references.pmid: 20614424
references.citation: Eur J Public Health. 2010 Oct;20(5):495-9
references.pmid: 20089677
references.citation: MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62
references.pmid: 20689501
references.citation: Lancet Infect Dis. 2012 Jan;12(1):36-44
references.pmid: 22032844
references.citation: Vaccine. 2010 Oct 28;28(46):7381-8
references.pmid: 20851086